PROM1 and neoplasm: The PLK1 activity controls a polarity checkpoint and compensates for BRAF/MAPK inhibition in CD133(+) tumor cells, suggesting the need for concurrent PLK1 inhibition to improve antitumor activity against a therapy-resistant cell compartment (69).